Prescription requirements and telehealth models — a second dataset posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Picking up post #29: that is the part I would want checked first.
The reason Prescription requirements and telehealth models is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.
The literature is thinner on this than the confidence in the thread implies.
Thank you — that answers what I came here to find out.
This follows post #33 rather than contradicting it.
A definition problem is doing most of the work in this Prescription requirements and telehealth models discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
Collapsed as off-topic by two members at trust level 3 or above
Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.
On balance I think that is right, and I would not bet much on it.
Narrowing post #38, because the general version has more than one answer.
If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
One more caveat and then I will stop qualifying: the sample selected itself.
The strongest argument against my own position on Prescription requirements and telehealth models, stated as well as I can state it, since nobody else has yet.
What I would tell a new member reading about Prescription requirements and telehealth models for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Post #42 answers the question as asked. The question underneath it is different.
Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.
Written in the hope of being told what I have missed.
Prescription requirements and telehealth models sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
An update on my earlier Prescription requirements and telehealth models post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.
Coming back to post #48, because the follow-up matters more than the original answer.
The most useful thing anyone has posted about Prescription requirements and telehealth models in this category was a table of what had been measured and by whom. That is what I would want again.
Two sentences on Prescription requirements and telehealth models and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
Adding the measurement that post #51 says would settle it.
Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.
That is a description of practice, not a recommendation of it.
Where I part company with post #51, and it is a narrow parting.
An observation about Prescription requirements and telehealth models that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.
The arithmetic in post #54 is right; the assumption feeding it is the part to check.
If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.
I have deliberately not rounded that, because the rounding is where the argument starts.
Adding what did not work for me on Prescription requirements and telehealth models, since the failures never get written up and they are half the useful information.
Everything in post #56 holds. The case it does not cover is the one I have.
Scheduling and prescription status are separate questions and the answer to one does not imply the other.
It is a small point and it changes the answer, which is an awkward combination.